

WWW.PROBECHEM.COM

## **Data Sheet**

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Cat. No. : CAS No. : Molecular Formula : Molecular Weight :		$\begin{array}{c} \overset{NH_2}{\underset{HS}{\overset{O}{\overset{I}}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}{\overset{I}{\overset{I}{\overset{I}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}}{\overset{I}}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}{\overset{I}}}{\overset{I}{\overset{I}{\overset{I}{\overset{I}}}{\overset{I}{\overset{I}}{\overset{I}{\overset{I}}}{\overset{I}{\overset{I}}{\overset{I}}}}}}}}}$
Solubility :	10 mM in DMSO	CAS: 533902-29-3

## **Biological Activity**

LCKLSL (Leu-Cys-Lys-Leu-Ser-Leu) is a potent, specific hexapeptide competitive inhibitor of Annexin A2 (AnxA2), inhibits tissue plasminogen activator (tPA)-binding capacity with IC50 of 11 uM.

LCKLSL targets the N-terminal tPA-binding site of AnxA2, binds efficiently to cell-surface AnxA2 compared with binding of the control peptide LGKLSL.

LCKLSL inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions. LCKLSL prevents hypoxia-induced angiogenic events in in vivo models of angiogenesis.

## References

Hajjar KA, et al. J Biol Chem. 1998 Apr 17;273(16):9987-93.

Valapala M, et al. J Cell Sci. 2011 May 1;124(Pt 9):1453-64.

Caution: Product has not been fully validated for medical applications. Lab Use Only! E-mail: tech@probechem.com